In the M1 cohort, patients with HER2+ and HER2− breast cancer had significantly higher serum miR-21 median levels than HDs, and patients with HER2+ breast cancer had higher serum miR-21 median levels than patients with HER2− breast cancer (Table S1), but that difference was not statistically significant. This evidence concerns the gene ERBB2 and breast cancer.